These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 12210813)

  • 21. Quality assessment of spontaneous triggered adverse event reports received by the Food and Drug Administration.
    Brajovic S; Piazza-Hepp T; Swartz L; Dal Pan G
    Pharmacoepidemiol Drug Saf; 2012 Jun; 21(6):565-70; discussion 571-2. PubMed ID: 22359404
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pemetrexed in malignant pleural mesothelioma.
    Hazarika M; White RM; Booth BP; Wang YC; Ham DY; Liang CY; Rahman A; Gobburu JV; Li N; Sridhara R; Morse DE; Lostritto R; Garvey P; Johnson JR; Pazdur R
    Clin Cancer Res; 2005 Feb; 11(3):982-92. PubMed ID: 15709163
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An evaluation of a data mining signal for amyotrophic lateral sclerosis and statins detected in FDA's spontaneous adverse event reporting system.
    Colman E; Szarfman A; Wyeth J; Mosholder A; Jillapalli D; Levine J; Avigan M
    Pharmacoepidemiol Drug Saf; 2008 Nov; 17(11):1068-76. PubMed ID: 18821724
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Potential glucosamine-warfarin interaction resulting in increased international normalized ratio: case report and review of the literature and MedWatch database.
    Knudsen JF; Sokol GH
    Pharmacotherapy; 2008 Apr; 28(4):540-8. PubMed ID: 18363538
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antipsychotics, glycemic disorders, and life-threatening diabetic events: a Bayesian data-mining analysis of the FDA adverse event reporting system (1968-2004).
    DuMouchel W; Fram D; Yang X; Mahmoud RA; Grogg AL; Engelhart L; Ramaswamy K
    Ann Clin Psychiatry; 2008; 20(1):21-31. PubMed ID: 18297583
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diplopia, blepharoptosis, and ophthalmoplegia and 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitor use.
    Fraunfelder FW; Richards AB
    Ophthalmology; 2008 Dec; 115(12):2282-5. PubMed ID: 18930555
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action.
    Wysowski DK; Nourjah P; Swartz L
    Arch Intern Med; 2007 Jul; 167(13):1414-9. PubMed ID: 17620536
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adolescent use of insulin and patient-controlled analgesia pump technology: a 10-year Food and Drug Administration retrospective study of adverse events.
    Cope JU; Morrison AE; Samuels-Reid J
    Pediatrics; 2008 May; 121(5):e1133-8. PubMed ID: 18450857
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quinine-induced hemolytic-uremic syndrome.
    Crum NF; Gable P
    South Med J; 2000 Jul; 93(7):726-8. PubMed ID: 10923967
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risks of the consumption of beverages containing quinine.
    Brasić JR
    Psychol Rep; 2003 Dec; 93(3 Pt 2):1022-4. PubMed ID: 14765563
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Finding, evaluating, and managing drug-related risks: approaches taken by the US Food and Drug Administration (FDA).
    Weaver J; Grenade LL; Kwon H; Avigan M
    Dermatol Ther; 2009; 22(3):204-15. PubMed ID: 19453344
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adverse events associated with the use of complementary medicine and health supplements: an analysis of reports in the Singapore Pharmacovigilance database from 1998 to 2009.
    Patel DN; Low WL; Tan LL; Tan MM; Zhang Q; Low MY; Chan CL; Koh HL
    Clin Toxicol (Phila); 2012 Jul; 50(6):481-9. PubMed ID: 22738039
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Quinine associated blindness.
    Townend BS; Sturm JW; Whyte S
    Aust Fam Physician; 2004 Aug; 33(8):627-8. PubMed ID: 15373380
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Benign nocturnal leg cramps. Current controversies over use of quinine.
    Leclerc KM; Landry FJ
    Postgrad Med; 1996 Feb; 99(2):177-8, 181-4. PubMed ID: 8632965
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Thrombocytopenia as an adverse effect of complementary and alternative medicines, herbal remedies, nutritional supplements, foods, and beverages.
    Royer DJ; George JN; Terrell DR
    Eur J Haematol; 2010 May; 84(5):421-9. PubMed ID: 20525061
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Indoor tanning injuries: an evaluation of FDA adverse event reporting data.
    Dowdy JC; Sayre RM; Shepherd JG
    Photodermatol Photoimmunol Photomed; 2009 Aug; 25(4):216-20. PubMed ID: 19614901
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety of quinine.
    Med Lett Drugs Ther; 2010 Nov; 52(1350):88. PubMed ID: 21045762
    [No Abstract]   [Full Text] [Related]  

  • 40. Quinine-induced thrombocytopenia following intravenous use of heroin.
    Christie DJ; Walker RH; Kolins MD; Wilner FM; Aster RH
    Arch Intern Med; 1983 Jun; 143(6):1174-5. PubMed ID: 6860046
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.